• Home
  • Biointron Biological
  • Webinar: Accelerating Antibody Drug Discovery with Biointron's AbDrop™ and Cyagen's HUGO-Ab™
Webinar
24 Dec 2024

Webinar: Accelerating Antibody Drug Discovery with Biointron's AbDrop™ and Cyagen's HUGO-Ab™

Watch Webinar

Biointron's latest webinar features Shun Zhou, Ph.D, the R&D Director at Cyagen: “Accelerating Antibody Discovery with Fully Human Antibody Mouse HUGO-Ab™ and Single B Cell Screening Technology AbDrop™”

This topic explores the revolutionary potential of the genome-edited mouse HUGO-Ab, where endogenous VH and VL genes are replaced by fully human VH and VL genes in situ, enabling the generation of fully human antibody molecules. When combined with microfluidic technology-enhanced single B cell screening, this approach allows for the high-throughput and efficient discovery of antibody drug molecules.

Content provided by our supplier

Biointron Biological

  • US
  • 2024
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
Contract Research Organisation (CRO)
Primary activities
Contract Research Organisation
View company profile

Other Content from Biointron Biological (2)

  • Full Service Brochure - Antibody Discovery, Production, and Optimization

    Brochure Full Service Brochure - Antibody Discovery, Production, and Optimization

    Take a look at our products in this handy brochure!
  • Biointron Insights: Antibody Industry Report (Q3 2024 Insights, Trends & Analysis)

    Technical Data Biointron Insights: Antibody Industry Report (Q3 2024 Insights, Trends & Analysis)

    This report aims to explore the events and trends of the biopharmaceutical industry in Q3 (July, August, September).
    https://www.biointron.com/industry-trends/biointron-insights-antibody-industry-report-q3-2024-insights-trends-analysis.html

    This quarter saw an increase in research trends in higher drug–antibody ratios for antibody-drug conjugates (ADCs), with promising approaches to address the problem of high hydrophobicity. Positive results in various clinical trials for anti-TIGIT therapies have also excited the field, with safety and pharmacovigilance at the center after numerous failures. Here, we give an example of a promising monoclonal antibody in development.

    To learn more, download the trends report here: https://www.biointron.com/industry-trends/biointron-insights-antibody-industry-report-q3-2024-insights-trends-analysis.html